Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
CorMedix Therapeutics clinical trials
The registry lists 49 studies whose lead sponsor is CorMedix Therapeutics or one of 5 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Keep track of what changes. Save the CorMedix Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to CorMedix Therapeutics.
- Melinta Therapeutics, Inc.32 studies →Acquired — became part of CorMedix Therapeutics, Aug 29, 2025 · source ↗
Something wrong?
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)6 studies →Acquired — became part of CorMedix Therapeutics, Aug 29, 2025 · source ↗
Something wrong?
- CorMedix4 studiesSame company
Something wrong?
- CorMedix Therapeutics2 studiesSame company
Something wrong?
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)2 studies →Acquired — became part of CorMedix Therapeutics, Aug 29, 2025 · source ↗
Something wrong?
- Melinta Therapeutics, LLC2 studies →Acquired — became part of CorMedix Therapeutics, Aug 29, 2025 · source ↗
Something wrong?
- Targanta Therapeutics Corporation1 study →Acquired — became part of CorMedix Therapeutics, Aug 29, 2025 · source ↗
Something wrong?
Focus areas
Conditions CorMedix Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 49 of 49.
- Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of AgeRecruitingNCT06714864Phase 4
- Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)RecruitingNCT06822426Phase 3
- A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy AdultsTerminatedNCT06612255Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute PyelonephritisActive, not recruitingNCT06672978Phase 2
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) · First submitted before Rempex became part of CorMedix Therapeutics
- Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial InfectionsCompletedNCT02687906Phase 1
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) · First submitted before Rempex became part of CorMedix Therapeutics
- Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical TrialsNo longer availableNCT06707480
Sponsor listed in the registry: CorMedix
- Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsCompletedNCT02134301Phase 1
Sponsor listed in the registry: Melinta Therapeutics, LLC · First submitted before Melinta Therapeutics, LLC became part of CorMedix Therapeutics
- Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin InfectionsCompletedNCT05599295Phase 2
Sponsor listed in the registry: Melinta Therapeutics, LLC · First submitted before Melinta Therapeutics, LLC became part of CorMedix Therapeutics
- Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream InfectionCompletedNCT02651428Phase 3
Sponsor listed in the registry: CorMedix
- A Study to Assess the Cardiac Safety of Oritavancin in Healthy ParticipantsCompletedNCT01762839Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Oritavancin on the Results of Multiple Coagulation Tests in Healthy VolunteersCompletedNCT02357524Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy VolunteersCompletedNCT01784536Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy SubjectsCompletedNCT02470702Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy SubjectsCompletedNCT02340988Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy AdultsCompletedNCT02802631Phase 1
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) · First submitted before Rempex became part of CorMedix Therapeutics
- A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World SettingCompletedNCT03160040
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) · First submitted before Rempex became part of CorMedix Therapeutics
- Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)CompletedNCT01252719Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionCompletedNCT01252732Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Relative Exposure and Safety Study of Kimyrsa in ABSSSI PatientsCompletedNCT03873987Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast AgentWithdrawnNCT01391520Phase 3
Sponsor listed in the registry: CorMedix
- Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial PneumoniaCompletedNCT02679573Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin InfectionsCompletedNCT01283581Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal InsufficiencyTerminatedNCT02808052Phase 1
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) · First submitted before Rempex became part of CorMedix Therapeutics
- Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in AdultsCompletedNCT02168946Phase 3
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) · First submitted before Rempex became part of CorMedix Therapeutics
- A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaWithdrawnNCT03006679Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy VolunteersCompletedNCT03564158Phase 1
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) · First submitted before Rempex became part of CorMedix Therapeutics
- Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial PneumoniaTerminatedNCT02605122Phase 2/3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy AdultsCompletedNCT03534622Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated GonorrheaTerminatedNCT02015637Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and APCompletedNCT02166476Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Study of Cases of Serious Infections Due to Carbapenem-Resistant EnterobacteriaceaeCompletedNCT02420366
Sponsor listed in the registry: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) · First submitted before Rempex became part of CorMedix Therapeutics
- A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World SettingCompletedNCT03159403
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01984684Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01811732Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With GonorrheaCompletedNCT02210325Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Pharmacokinetics and Safety of Solithromycin in Adolescents and ChildrenCompletedNCT02268279Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without CirrhosisCompletedNCT02510599Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaCompletedNCT01756339Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaCompletedNCT01168713Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital GonorrheaCompletedNCT01591447Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaCompletedNCT01968733Phase 3
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Pharmacokinetics and Safety of Solithromycin Capsules in AdolescentsCompletedNCT01966055Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy SubjectsCompletedNCT02505997Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Safety and Efficacy Study of Oxazolidinone to Treat PneumoniaCompletedNCT00640926Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic ImpairmentCompletedNCT02245243Phase 1
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin InfectionsCompletedNCT00719810Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin InfectionsCompletedNCT00646958Phase 2
Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics
- Deferiprone for the Prevention of Contrast-Induced Acute Kidney InjuryCompletedNCT01146925Phase 2
Sponsor listed in the registry: CorMedix
- A Study for Patients With Complicated Skin and Skin Structure InfectionsCompletedNCT00514527Phase 2
Sponsor listed in the registry: Targanta Therapeutics Corporation · First submitted before Targanta Therapeutics Corporation became part of CorMedix Therapeutics